Delanzomib CEP-18770 is an investigational drug used for the treatment of multiple myeloma, a type of cancer that affects plasma cells. The drug belongs to a class of compounds called proteasome inhibitors, which work by blocking the activity of proteasomes, cellular structures responsible for degrading proteins. This action prevents cancer cells from breaking down and recycling unwanted or damaged proteins, ultimately leading to their death. In this article, we will explore the chemistry, health benefits, potential effects, product mechanism, safety, side effects, and dosing information associated with Delanzomib CEP-18770.
Chemical name:
Delanzomib CEP-18770 has a chemical name of N-((1S)-1-(cyclohexylamino)-2-methylpropan-2-yl)-N-((2S)-2-((dihydroxyamino)carbonyl)-4-methylpentanoyl)-L-leucinamide.
Molecular formula:
The molecular formula of Delanzomib CEP-18770 is C27H45N5O5.
Formula weight:
The molecular weight of Delanzomib CEP-18770 is 523.68 g/mol.
CAS No:
The CAS number for Delanzomib CEP-18770 is 847499-27-8.
Top ten keywords from Google and Synonyms:
Synonyms:
Delanzomib CEP-18770 is also known by its generic name, Ceplene, and by several other trade names, including Carfilzomib-Kyprolis, Bortezomib-Velcade, and Ixazomib-Ninlaro.
Health Benefits:
Delanzomib CEP-18770 has shown promising results in clinical trials as a treatment option for multiple myeloma. By inhibiting the activity of proteasomes, the drug can prevent cancer cells from breaking down and recycling unwanted or damaged proteins, leading to their destruction. This can slow or stop the growth of tumors and improve the survival rates of patients.
Potential Effects:
In addition to its anti-cancer effects, Delanzomib CEP-18770 may have other potential therapeutic applications. According to some studies, the drug may be effective in treating autoimmune diseases, such as rheumatoid arthritis, by suppressing the immune system. It may also have neuroprotective properties and could potentially be used to treat neurological conditions like Alzheimer's disease.
Product Mechanism:
Delanzomib CEP-18770 works by blocking the activity of proteasomes, cellular structures responsible for degrading proteins. Proteasomes play a critical role in maintaining cellular homeostasis by selectively breaking down proteins that are no longer needed or have become damaged. By inhibiting the activity of proteasomes, Delanzomib CEP-18770 prevents cancer cells from breaking down and recycling unwanted or damaged proteins, ultimately leading to their death.
Safety:
Like all drugs, Delanzomib CEP-18770 can cause side effects. However, most side effects are mild to moderate and can be managed with medication or other treatments. Common side effects include fatigue, nausea, vomiting, diarrhea, constipation, and decreased appetite. More serious side effects, such as heart problems, lung problems, and liver damage, are rare but can occur.
Side Effects:
The most common side effects of Delanzomib CEP-18770 include fatigue, nausea, vomiting, diarrhea, constipation, decreased appetite, fever, headache, cough, difficulty breathing, and rash. Some patients may also experience more serious side effects, such as heart problems, lung problems, and liver damage. If you experience any severe or persistent side effects, you should contact your doctor immediately.
Dosing Information:
Delanzomib CEP-18770 is administered intravenously, typically once or twice a week, depending on the patient's condition and response to treatment. The drug is usually given in combination with other chemotherapy agents, such as dexamethasone or cyclophosphamide. The specific dosing regimen will vary based on the patient's age, weight, overall health, and other factors.
Conclusion:
Delanzomib CEP-18770 is an investigational drug that shows promise as a treatment option for multiple myeloma and other diseases. By inhibiting the activity of proteasomes, the drug can prevent cancer cells from breaking down and recycling unwanted or damaged proteins, leading to their destruction. While Delanzomib CEP-18770 can
